Abstract
The discovery of a series of novel and orally efficacious type II calcimimetics, developed from the lead compound 1, is described herein. Compound 22 suppressed plasma PTH levels relative to vehicle when dosed orally in a rat pharmacodynamic model.
Copyright (c) 2010 Elsevier Ltd. All rights reserved.
MeSH terms
-
Administration, Oral
-
Animals
-
Benzylamines / administration & dosage
-
Benzylamines / chemistry*
-
Benzylamines / pharmacokinetics
-
Benzylamines / pharmacology*
-
Male
-
Parathyroid Hormone / antagonists & inhibitors*
-
Parathyroid Hormone / blood*
-
Rats
-
Rats, Sprague-Dawley
-
Receptors, Calcium-Sensing / metabolism*
-
Structure-Activity Relationship
Substances
-
Benzylamines
-
Parathyroid Hormone
-
Receptors, Calcium-Sensing
-
dibenzylamine